MCM5 is a Novel Therapeutic Target for Glioblastoma

References

• Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82. doi:10.1016/j.pharmthera.2015.05.005
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–1850. doi:10.1001/jama.2013.280319
   PubMed Web of Science ®Google Scholar
• Feng B, Lu X, Zhang G, Zhao L, Mei D. STING agonist delivery by lipid calcium phosphate nanoparticles enhances immune activation for neuroblastoma. Acta Materia Medica. 2023;2(2):216–227. doi:10.15212/amm-2023-0011
   Google Scholar
• Ortiz R, Perazzoli G, Cabeza L, et al. Temozolomide: an Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021;19(4):513–537. doi:10.2174/1570159x18666200626204005
   PubMed Web of Science ®Google Scholar
• Iturrioz-Rodríguez N, Sampron N, Matheu A. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Theranostics. 2023;13(9):2734–2756. doi:10.7150/thno.82005
   PubMed Web of Science ®Google Scholar
• Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018;20(12):1566–1572. doi:10.1093/neuonc/noy072
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir. 2018;58(10):405–421. doi:10.2176/nmc.ra.2018-0141
   PubMed Web of Science ®Google Scholar
• Roh J, Im M, Kang J, Youn B, Kim W. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. Anim Cells Syst (Seoul). 2023;27(1):19–28. doi:10.1080/19768354.2023.2175497
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Qin Z, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 2021;17(3):291–306. doi:10.1080/17425255.2021.1887139
   PubMed Web of Science ®Google Scholar
• Erasimus H, Gobin M, Niclou S, Van Dyck E. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res. 2016;769:19–35. doi:10.1016/j.mrrev.2016.05.005
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. doi:10.1016/j.gendis.2016.04.007
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Preusser M, Roth P, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896. doi:10.1016/j.ctrv.2019.101896
   PubMed Web of Science ®Google Scholar
• Yang K, Wu Z, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21(1):39. doi:10.1186/s12943-022-01513-z
   PubMed Web of Science ®Google Scholar
• Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. doi:10.1186/s13046-016-0303-5
   PubMed Web of Science ®Google Scholar
• Chong JP, Thömmes P, Blow JJ. The role of MCM/P1 proteins in the licensing of DNA replication. Trends Biochem Sci. 1996;21(3):102–106.
   PubMed Web of Science ®Google Scholar
• Pellegrini L. The CMG DNA helicase and the core replisome. Curr Opin Struct Biol. 2023;81:102612. doi:10.1016/j.sbi.2023.102612
   PubMed Web of Science ®Google Scholar
• Tanaka S, Araki H. Helicase activation and establishment of replication forks at chromosomal origins of replication. Cold Spring Harbor Perspect. Biol. 2013;5(12):a010371. doi:10.1101/cshperspect.a010371
   PubMed Web of Science ®Google Scholar
• Xiang S, Reed DR, Alexandrow MG. The CMG helicase and cancer: a tumor “engine” and weakness with missing mutations. Oncogene. 2023;42(7):473–490. doi:10.1038/s41388-022-02572-8
   PubMed Web of Science ®Google Scholar
• Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology. 2010;57(1):1–13. doi:10.1111/j.1365-2559.2010.03592.x
   PubMed Web of Science ®Google Scholar
• Gao H, Wei H, Yang Y, et al. Phase separation of DDX21 promotes colorectal cancer metastasis via MCM5-dependent EMT pathway. Oncogene. 2023;42(21):1704–1715. doi:10.1038/s41388-023-02687-6
   PubMed Web of Science ®Google Scholar
• Jiang Y, Guo H, Tong T, et al. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Therapy. 2022;30(1):448–467. doi:10.1016/j.ymthe.2021.06.006
   PubMed Web of Science ®Google Scholar
• Zhang LL, Li Q, Zhong DS, Zhang WJ, Sun XJ, Zhu Y. MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer. Front Cell Develop Biol. 2021;9:669132. doi:10.3389/fcell.2021.669132
   PubMedGoogle Scholar
• Yang Y, Yan Y, Yin J, et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal Transduction Targeted Therapy. 2023;8(1):63. doi:10.1038/s41392-023-01316-8
   PubMed Web of Science ®Google Scholar
• Mao W, Ding Z, Wang K, Chen M. Cuproptosis-related MTF1 inhibits kidney renal clear cell carcinoma progression by suppressing proliferation and regulating immune cell infiltration. Acta Materia Medica. 2023;2(3):310–322. doi:10.15212/amm-2023-0016
   Google Scholar
• Li J, Ma S, Zheng Y, et al. Prognostic value and immune infiltration analyses of cuproptosis-related genes in hepatocellular carcinoma. Acta Materia Medica. 2023;2(4):386–399. doi:10.15212/amm-2023-0035
   Google Scholar
• Namdar M, Kearsey SE. Analysis of Mcm2-7 chromatin binding during anaphase and in the transition to quiescence in fission yeast. Exp Cell Res. 2006;312(17):3360–3369. doi:10.1016/j.yexcr.2006.07.001
   PubMed Web of Science ®Google Scholar
• Sharma G, Sharma A, Krishna M, Ahluwalia P, Gautam G. Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: a systematic review and meta-analysis. Urol Oncol. 2022;40(6):235–242. doi:10.1016/j.urolonc.2022.03.001
   PubMed Web of Science ®Google Scholar
• Gong B, Ma M, Yang X, Xie W, Luo Y, Sun T. MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma. Int Urol Nephrol. 2019;51(9):1517–1526. doi:10.1007/s11255-019-02169-3
   PubMed Web of Science ®Google Scholar
• Mao J, Shen J, Lu X, et al. MCM5 is an oncogene of colon adenocarcinoma and promotes progression through cell cycle control. Acta Histochem. 2023;125(6):152072. doi:10.1016/j.acthis.2023.152072
   PubMed Web of Science ®Google Scholar
• Mio C, Lavarone E, Conzatti K, et al. MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer. 2016;23(4):335–347. doi:10.1530/erc-15-0322
   PubMed Web of Science ®Google Scholar
• Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20(1):206. doi:10.1186/s12967-022-03405-8
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction Targeted Therapy. 2023;8(1):160. doi:10.1038/s41392-023-01419-2
   PubMed Web of Science ®Google Scholar
• Shi J, Li Y, Jia R, Fan X. The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int, J, Cancer. 2020;146(8):2078–2088. doi:10.1002/ijc.32662
   PubMed Web of Science ®Google Scholar
• Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1):4. doi:10.1186/s13045-019-0829-z
   PubMed Web of Science ®Google Scholar
• Li B, Zheng L, Ye J, et al. CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways. Sci China Life Sci. 2022;65(8):1481–1497. doi:10.1007/s11427-022-2108-x
   PubMed Web of Science ®Google Scholar
• Wei Z, Wang S, Xu Y, et al. MYC reshapes CTCF-mediated chromatin architecture in prostate cancer. Nat Commun. 2023;14(1):1787. doi:10.1038/s41467-023-37544-3
   PubMed Web of Science ®Google Scholar
• Fang Z, Gong C, Yu S, et al. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer Lett. 2018;415:58–72. doi:10.1016/j.canlet.2017.11.040
   PubMed Web of Science ®Google Scholar
• Lai Q, Li Q, He C, et al. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. Aging. 2020;12(16):16270–16293. doi:10.18632/aging.103648
   PubMedGoogle Scholar
• Masic D, Fee K, Bell H, et al. Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia. Haematologica. 2023;108(4):981–992. doi:10.3324/haematol.2022.281177
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu Z, Liu Z, et al. MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1. Autophagy. 2013;9(12):2069–2086. doi:10.4161/auto.26447
   PubMed Web of Science ®Google Scholar
• Arrieta VA, Dmello C, McGrail DJ, et al. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023;133(2).
   Web of Science ®Google Scholar
• Ghouzlani A, Kandoussi S, Tall M, Reddy KP, Rafii S, Badou A. Immune Checkpoint Inhibitors in Human Glioma Microenvironment. Front Immunol. 2021;12:679425. doi:10.3389/fimmu.2021.679425
   PubMedGoogle Scholar
• Liu H, Zhao Q, Tan L, et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell. 2023;41(4):693–710.e8. doi:10.1016/j.ccell.2023.03.004
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi:10.1126/science.aar6711
   PubMed Web of Science ®Google Scholar
• Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–177. doi:10.1038/s41571-022-00719-w
   PubMed Web of Science ®Google Scholar
• Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;22(4):610–616. doi:10.1200/jco.2004.07.060
   PubMed Web of Science ®Google Scholar
• Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009;8(4):493–499. doi:10.1517/14740330902918281
   PubMed Web of Science ®Google Scholar
• Sengupta S, Marrinan J, Frishman C, Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin Dev Immunol. 2012;2012:831090. doi:10.1155/2012/831090
   PubMed Web of Science ®Google Scholar
• Nabors LB, Lamb LS, Goswami T, Rochlin K, Youngblood SL. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions. Front Immunol. 2024;15:1299044. doi:10.3389/fimmu.2024.1299044
   PubMed Web of Science ®Google Scholar
• Lamb LS, Pereboeva L, Youngblood S, et al. A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. Sci Rep. 2021;11(1):21133. doi:10.1038/s41598-021-00536-8
   PubMed Web of Science ®Google Scholar